The submission is the first to be filed in Europe for a gene therapy product for any type of hemophilia
The submission is the first to be filed in Europe for a gene therapy product for any type of hemophilia
The drug is the first oral CGRP receptor antagonist approved to treat acute migraines
The drug has been approved for insomnia characterised by difficulties with sleep onset and/or sleep maintenance
The novel gene therapy is being developed for the lysosomal storage disease Sanfilippo syndrome type A (MPS IIIA)
Sarepta will receive $1.15 billion upfront and an equity investment
Doctors will be able to prescribe the drug from January 6
The approval marks a “significant milestone in Ebola prepardness and prevention”
US regulators have declined ViiV Healthcare’s application to market an investigational long-acting regimen for the treatment of HIV
Juvisé has paid upfront $181 million to AZ for the medicines
The 2020 PharmaTimes International Clinical Researcher of the Year competition will be closing for entry on the 23rd January 2020.
Rheos will receive an upfront cash payment of $42.5 million, with up to $90 million available for specified research and preclinical development milestones.
The decision means that Wales is the first country in the UK to recommend funding for the drug, after the SMC refused it.
Major depressive disorder affects approximately 40 million people across Europe and 1.8 million adults in England alone.
The decision is based on results from the Phase III SELECT studies.
The new technology uses microscopic clusters of bubbles and liquid droplets to enhance the delivery of chemotherapy drugs to tumours.